share_log

大摩：予国药控股(01099)“增持”评级 目标价下调至29港元

Daimo: Yosinopharm Holdings (01099) “increase in holdings” rating, target price lowered to HK$29

Zhitong Finance ·  Dec 21, 2023 10:25

Daimo lowered Sinopharm Holdings' profit forecast for 2023-2030 by about 2%.

The Zhitong Finance app learned that according to a research report published by Daimo, based on the third-quarter results of Sinopharm Holdings (01099) and recent monthly trends, its profit forecast for 2023 to 2030 was lowered by about 2% to reflect the decline in sales and gross margin. The target price was reduced from HK$30 to HK$29 accordingly, and the rating was “increased”.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment